Idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis (IPF) is a clinical syndrome and considered the most common and the most lethal form of pulmonary fibrosis corresponding to the histologic and imaging pattern of UIP. It is more common in middle age or elderly men and diagnosed by: 

  1. histological or imaging pattern of usual interstitial pneumonia (UIP) and
  2. absence of alternative causes such as drug toxicity, environmental exposure (e.g. asbestos) or collagen vascular disease (e.g. scleroderma, rheumatoid arthritis)

It tends to be commoner in males with most cases presenting in those over 50 years of age.

Patients typically present with progressive dyspnoea on exertion and chronic dry cough, finger clubbing, chest pain, fatigue, malaise, and weight loss. Pulmonary function test results may be normal in mild disease or shows restriction pattern (i.e. reduced vital capacity and total lung capacity but near normal residual volume). DLCO is commonly decreased even in with mild cases. 

A multidisciplinary approach in a tertiary setting is strongly advised. Contributions from pulmonologists, chest radiologists, and chest pathologists are crucial in reaching the correct diagnosis of IPF. 

ATS and ERS (American Thoracic Society and European Respiratory Society) have jointly agreed major and minor criteria for the diagnosis of IPF in the absence of a surgical lung biopsy 5:

  • exclusion of other known causes of interstitial lung disease (e.g. toxic effects of certain drugs, environmental exposures, connective tissue diseases) abnormal results of pulmonary function studies, including evidence of restriction (reduced vital capacity, often with an increased FEV1/FVC ratio) and impaired gas exchange (increased PaO2, decreased PaO2 with rest or exercise, or decreased DlCO)
  • bibasilar reticular abnormalities with minimal ground-glass opacities at high-resolution CT: definite UIP pattern on HRCT chest 
  • transbronchial lung biopsy or bronchoalveolar lavage shows no features to support an alternative diagnosis
  • age >50 years
  • insidious onset of otherwise unexplained dyspnoea on exertion
  • duration of illness >3 months
  • bibasilar inspiratory crackles (dry or “Velcro” type)

IPF as the name states it is idiopathic however there is an association with concurrent or previous history of smoking in 60% of patients and genetic factors. Up to 5–20% of patients with IPF have a family history of interstitial lung disease (ILD) or pulmonary fibrosis. More recently it has been shown that fibroblasts in this process demonstrate neoplastic or neoproliferative characteristics 11

The rs35705950 single-nucleotide polymorphism (SNP)—a promoter site of an airway mucin gene (MUC5B)—is strongly associated with IPF and familial pulmonary fibrosis and not seen in other secondary causes of lung fibrosis. Positive rs35705950 SNP in IPF patients is associated with slightly better prognosis and outcome. 

Histology shows a UIP pattern which is characterized by spatial and temporal heterogeneity. One of the hallmarks is the absence of inflammation.  Spatial heterogeneity denotes biopsy sample showing patchy lung involvement with normal lung interspace between diseased lung. Temporal heterogeneity denotes different stages of disease seen on a single specimen, including normal lung, interstitial fibrosis and fibroblastic foci 4.

The CT imaging findings complement the histology. It is more correct to describe the characteristic imaging pattern as UIP rather than IPF, the latter term assigned for the idiopathic clinical syndrome of UIP.

A UIP-pattern of fibrosis is characterised by honeycombing cysts and reticular septal thickening with subpleural and posterior basal predominance. Traction bronchiectasis can also be observed, however, this is a general feature of fibrosis not specific to the UIP-pattern 4. In a subgroup of patients the imaging findings of UIP overlap with NSIP and biopsy may be necessary to obtain the correct diagnosis.

The clinical course is that of gradual deterioration and the condition carries a rather poor prognosis with median survival ranging from 2.5 to 3.5 years from the time of diagnosis (at the time of initial writing) 2. Some reports have suggested a slowing of progression with treatment by pirfenidone or nintedanib 7,8.

Consider pulmonary fibrosis due to a known cause, such as:

Share article

Article information

rID: 16929
System: Chest
Tag: cases
Synonyms or Alternate Spellings:
  • Idiopathic pulmonary fibrosis (IPF)
  • IPF

Support Radiopaedia and see fewer ads

Cases and figures

  • Drag
    Case 1
    Drag here to reorder.
  • Drag
    Case 2
    Drag here to reorder.
  • Updating… Please wait.

    Alert accept

    Error Unable to process the form. Check for errors and try again.

    Alert accept Thank you for updating your details.